Bausch + Lomb
BLCO
Bausch + Lomb (BLCO) news
Recent news
Bausch + Lomb - combined potential peak sales for both therapies exceed $2 bln
AInvest Wire · 6d agoBausch + Lomb: Dual-action eye drop study fails primary endpoint vs lifitegrast alone at day 29
AInvest Wire · 6d agoBausch + Lomb - to advance dual-action eye drop into Phase 3
AInvest Wire · 6d agoBausch + Lomb reaffirms guidance
AInvest Wire · Aug 6, 2026Bausch Health CEO Thomas J. Appio joins Bausch + Lomb board
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.